Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
NASDAQ:SLRN
Holding SLRN?
Track your performance easily
SLRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.36 - $9.25
Previous Close$6.06
Volume336.76K
Average Volume (3M)898.14K
Market Cap
$604.84M
Enterprise Value-$29.33M
Total Cash (Recent Filing)$635.24M
Total Debt (Recent Filing)$1.07M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 13, 2024EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.06
Shares Outstanding99,808,262
10 Day Avg. Volume383,600
30 Day Avg. Volume898,145
Standard Deviation0.24
R-Squared0.10
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)1.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$10.83Price Target Upside84.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
ACELYRIN, INC. News
PremiumCompany Announcements
ACELYRIN, INC. Advances Key Drug Developments
PremiumPre-Earnings
Is SLRN a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentManagement seems very comfortable with the lonigutamab data and is already planning an end-of-Phase 2 meeting with the FDA prior to cohort 4, indicating confidence in the progress of clinical development.
Clinical TrialsThe odds are high that izokibep's Ph2/3 trial in uveitis will be positive, offering an attractive risk/reward skew.
Financial PerformanceThe company now projects a cash runway through mid-2027, providing financial stability for ongoing and future projects.
Bears Say
Investment DecisionsNo new investment will be made for izokibep in HS or PsA and they plan to make a similar decision on uveitis post its 4Q24 read out.
R&D StrategyAcelyrin announced the de-prioritization of izokibep in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA).
Workforce And DevelopmentSLRN is reducing 33% workforce and stopped development of SLRN-517.
---
Ownership Overview
13.92% Insiders
12.91% Mutual Funds
3.26% Other Institutional Investors
61.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLRN FAQ
What was ACELYRIN, INC.’s price range in the past 12 months?
ACELYRIN, INC. lowest stock price was $3.36 and its highest was $9.25 in the past 12 months.
What is ACELYRIN, INC.’s market cap?
Currently, no data Available
When is ACELYRIN, INC.’s upcoming earnings report date?
ACELYRIN, INC.’s upcoming earnings report date is Nov 13, 2024 which is 10 days ago.
How were ACELYRIN, INC.’s earnings last quarter?
ACELYRIN, INC. released its earnings results on Aug 13, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.78 by -$0.08.
Is ACELYRIN, INC. overvalued?
According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued.
Does ACELYRIN, INC. pay dividends?
ACELYRIN, INC. does not currently pay dividends.
What is ACELYRIN, INC.’s EPS estimate?
ACELYRIN, INC.’s EPS estimate is -$0.8.
How many shares outstanding does ACELYRIN, INC. have?
ACELYRIN, INC. has 99,808,266 shares outstanding.
What happened to ACELYRIN, INC.’s price movement after its last earnings report?
ACELYRIN, INC. reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.78. Following the earnings report the stock price went down -14.706%.
Which hedge fund is a major shareholder of ACELYRIN, INC.?
Among the largest hedge funds holding ACELYRIN, INC.’s share is Woodline Partners LP. It holds ACELYRIN, INC.’s shares valued at 9M.
---
ACELYRIN, INC. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.83 (84.18% Upside)
$10.83 (84.18% Upside)
Hedge Fund Trend
Increased
By 952.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.43%
12-Months-Change
Fundamentals
Return on Equity
-43.79%
Trailing 12-Months
Asset Growth
-21.96%
Trailing 12-Months
Company Description
ACELYRIN, INC.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
---
SLRN Earnings Call
Q2 2024
0:00 / 0:00
---
SLRN Stock 12 Month Forecast
Average Price Target
$10.83
▲(84.18% Upside)
Technical Analysis
Best Analysts Covering SLRN
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-29.35%
assigned a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -29.35% per trade.
---